Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892044780> ?p ?o ?g. }
- W2892044780 endingPage "1548" @default.
- W2892044780 startingPage "1538" @default.
- W2892044780 abstract "Human β-defensins contain an oncolytic motif that binds to tumor cell membranes and mediate permeabilization, rapid induction of cytolysis, and apoptosis. Previous studies have indicated that a fragment of the mature human β-defensin-1 (HBD1) peptide (DF) has antitumor properties. While targeted drug treatments using fusion proteins have been shown to increase drug efficacy, this phenomenon has not been studied for this defensin. Thus, in this study, we designed and prepared a fusion protein containing this HBD1 fragment and an epidermal growth factor receptor (EGFR)-targeting oligopeptide (Ec) as well as lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, which consists of an apoprotein (LDP) and a highly active enediyne (AE). The fusion protein (Ec-LDP-DF) and its enediyne-integrated fusion protein (Ec-LDP(AE)-DF) were then purified and used to treat lung carcinoma cells in culture as well as lung carcinoma xenograft mouse models. The multifunctional fusion protein Ec-LDP-DF was shown to effectively bind to EGFR-expressing tumor cells. Furthermore, the enediyne-energized Ec-LDP(AE)-DF analog exhibited extremely potent cytotoxicity in NSCLC cell lines and an IC50 less than 10-10 mol/L. Ec-LDP(AE)-DF also significantly inhibited the growth of human carcinoma A549 and H460 xenografts in athymic mice at well-tolerated doses. Treatment resulted in cell cycle arrest and apoptosis in a dose-dependent manner. EGF-stimulated EGFR phosphorylation was also abolished by Ec-LDP(AE)-DF. In summary, our understanding of the role of defensins in cancer development and progression is continually expanding, and Ec-LDP(AE)-DF is a promising cancer cell-targeting agent for NSCLC." @default.
- W2892044780 created "2018-09-27" @default.
- W2892044780 creator A5017134771 @default.
- W2892044780 creator A5029116476 @default.
- W2892044780 creator A5070151668 @default.
- W2892044780 creator A5070584261 @default.
- W2892044780 creator A5085760239 @default.
- W2892044780 date "2018-12-01" @default.
- W2892044780 modified "2023-10-03" @default.
- W2892044780 title "Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma" @default.
- W2892044780 cites W1517881884 @default.
- W2892044780 cites W1933816205 @default.
- W2892044780 cites W1973855168 @default.
- W2892044780 cites W1977685377 @default.
- W2892044780 cites W1988901915 @default.
- W2892044780 cites W2012815507 @default.
- W2892044780 cites W2016440234 @default.
- W2892044780 cites W2026819869 @default.
- W2892044780 cites W2036437239 @default.
- W2892044780 cites W2039089155 @default.
- W2892044780 cites W2048498897 @default.
- W2892044780 cites W2051701435 @default.
- W2892044780 cites W2052184476 @default.
- W2892044780 cites W2054429359 @default.
- W2892044780 cites W2060020062 @default.
- W2892044780 cites W2063855716 @default.
- W2892044780 cites W2082431893 @default.
- W2892044780 cites W2104159258 @default.
- W2892044780 cites W2122328108 @default.
- W2892044780 cites W2127217536 @default.
- W2892044780 cites W2142720273 @default.
- W2892044780 cites W2148659975 @default.
- W2892044780 cites W2215928721 @default.
- W2892044780 cites W2231098525 @default.
- W2892044780 cites W2498997389 @default.
- W2892044780 cites W2544345721 @default.
- W2892044780 cites W2582492142 @default.
- W2892044780 cites W2584601959 @default.
- W2892044780 cites W2590085041 @default.
- W2892044780 cites W2592528779 @default.
- W2892044780 cites W2604128748 @default.
- W2892044780 cites W2776380045 @default.
- W2892044780 cites W2777232569 @default.
- W2892044780 cites W2883904371 @default.
- W2892044780 doi "https://doi.org/10.1038/s41374-018-0109-5" @default.
- W2892044780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30206309" @default.
- W2892044780 hasPublicationYear "2018" @default.
- W2892044780 type Work @default.
- W2892044780 sameAs 2892044780 @default.
- W2892044780 citedByCount "10" @default.
- W2892044780 countsByYear W28920447802019 @default.
- W2892044780 countsByYear W28920447802020 @default.
- W2892044780 countsByYear W28920447802021 @default.
- W2892044780 countsByYear W28920447802023 @default.
- W2892044780 crossrefType "journal-article" @default.
- W2892044780 hasAuthorship W2892044780A5017134771 @default.
- W2892044780 hasAuthorship W2892044780A5029116476 @default.
- W2892044780 hasAuthorship W2892044780A5070151668 @default.
- W2892044780 hasAuthorship W2892044780A5070584261 @default.
- W2892044780 hasAuthorship W2892044780A5085760239 @default.
- W2892044780 hasBestOaLocation W28920447801 @default.
- W2892044780 hasConcept C104317684 @default.
- W2892044780 hasConcept C109316439 @default.
- W2892044780 hasConcept C123894998 @default.
- W2892044780 hasConcept C153911025 @default.
- W2892044780 hasConcept C154317977 @default.
- W2892044780 hasConcept C170493617 @default.
- W2892044780 hasConcept C185592680 @default.
- W2892044780 hasConcept C190283241 @default.
- W2892044780 hasConcept C202751555 @default.
- W2892044780 hasConcept C2776498113 @default.
- W2892044780 hasConcept C2779281246 @default.
- W2892044780 hasConcept C2779438470 @default.
- W2892044780 hasConcept C40767141 @default.
- W2892044780 hasConcept C502942594 @default.
- W2892044780 hasConcept C54355233 @default.
- W2892044780 hasConcept C55493867 @default.
- W2892044780 hasConcept C81885089 @default.
- W2892044780 hasConcept C86803240 @default.
- W2892044780 hasConceptScore W2892044780C104317684 @default.
- W2892044780 hasConceptScore W2892044780C109316439 @default.
- W2892044780 hasConceptScore W2892044780C123894998 @default.
- W2892044780 hasConceptScore W2892044780C153911025 @default.
- W2892044780 hasConceptScore W2892044780C154317977 @default.
- W2892044780 hasConceptScore W2892044780C170493617 @default.
- W2892044780 hasConceptScore W2892044780C185592680 @default.
- W2892044780 hasConceptScore W2892044780C190283241 @default.
- W2892044780 hasConceptScore W2892044780C202751555 @default.
- W2892044780 hasConceptScore W2892044780C2776498113 @default.
- W2892044780 hasConceptScore W2892044780C2779281246 @default.
- W2892044780 hasConceptScore W2892044780C2779438470 @default.
- W2892044780 hasConceptScore W2892044780C40767141 @default.
- W2892044780 hasConceptScore W2892044780C502942594 @default.
- W2892044780 hasConceptScore W2892044780C54355233 @default.
- W2892044780 hasConceptScore W2892044780C55493867 @default.
- W2892044780 hasConceptScore W2892044780C81885089 @default.
- W2892044780 hasConceptScore W2892044780C86803240 @default.
- W2892044780 hasIssue "12" @default.